Bill Title: Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.

Spectrum: Slight Partisan Bill (Democrat 7-3)

Status: (Passed) 2016-12-05 - Approved P.L.2016, c.73. [S2024 Detail]

Text: Latest bill text (Chaptered) [HTML]

---

PolitiCorps Conversations

Start PolitiCorps Debate

Title	PolitiCorps	Access	Comments	Views	Last Post
There are no visible public or private PolitiCorps discussions concerning the 2016 New Jersey S2024 at this time.

Social Comments on NJ S2024